Technology Listings

Prostaglandin EP2 Receptor Antagonists for Reducing Inflammation


Potential small molecule therapeutic for treatment of peripheral inflammation, neurological disorders and carcinogenesis.

Key Benefits
  • EP2 is a key receptor for cancer progression, peripheral and brain inflammation.
  • Lead compound candidates display high EP2 potency and selectivity.
  • Compound effectively inhibits inflammation.
Market Summary

The inflammatory response is a significant component of the immune system. Both acute and chronic inflammation contribute to well over 10 million cases in the United States. These cases include post-operative cognitive dysfunction (POCD), post-operative delirium, Alzheimer’s disease, traumatic brain injury (TBI), carcinogenesis and many more. Such instances of inflammation have been linked to the activation of EP2 receptor, which promotes inflammation, tumor growth and progression. No other EP2 specific antagonists are on the market and there remains a large unmet need for anti-inflammatory drugs with minimal side effects.

Technical Summary

To address the issues involved with targeted cancer therapy and global inhibition of COX enzymes, researchers at Emory University developed potent and selective antagonists - for prostaglandin-E2receptor EP2. Prostaglandin E2 (PGE2) is the dominant enzymatic product of COX-2, and EP2 activation by PGE2 has been shown to promote inflammatory reactions in several tissues including brain. The lead compound candidates display a 5,000-fold selectivity over the highly related EP4 receptor. Due to the ability of the lead compound candidates to prevent inflammation, as well as cancer progression, the potential market extends to patients of various physiological consequences associated with EP2 activation.

Developmental Stage
  • Lead candidates have been identified.
  • In vitro and in vivo proof-of-concept (POC) data available
Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Nationalized PCT - United States United States 14/126,689 9,518,044 12/16/2013 12/13/2016 1/1/2033 Issued
Nationalized PCT - Foreign EP 12803492.3 2721011 12/20/2013 8/10/2017 6/19/2032 Issued
Nationalized PCT - United States United States 15/307,051 10,052,332 10/27/2016 8/21/2018 4/17/2035 Issued
Nationalized PCT - Foreign EP 15785214.6   11/25/2016     Pending
Continuation United States 15/365,850 10,040,783 11/30/2016 8/7/2018 6/19/2032 Issued
Continuation United States 16/037,374 10,568,889 7/17/2018 2/25/2020 4/17/2035 Issued
Divisional United States 16/686,046 11/15/2019     Pending
Tech ID: NCS.14
Published: 5/18/2015

Cale Lennon
Director, Licensing
Emory University

Jianxiong Jiang
Pahk Thepchatri
Raymond Dingledine
Thota Ganesh
Yuhong Du

Small Molecule